

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number  
**WO 2005/096992 A1**

(51) International Patent Classification<sup>7</sup>: **A61F 2/06**

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2004/004133

(22) International Filing Date: 2 April 2004 (02.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ARTERIAL REMODELLING TECHNOLOGIES, INC.** [FR/FR]; 3, rue de Verdun, Bât. G, F-78590 Noisy-Le-Roi (FR).

**Declarations under Rule 4.17:**

— *as to the identity of the inventor (Rule 4.17(i)) for all designations*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LAFONT, Antoine** [FR/FR]; 46, rue de Bac, F-75007 Paris (FR). **PIRANDA STATICE SANTE, Serge** [FR/FR]; Z.I. des Tilleroyes, 9, rue Thomas Edison, F-25000 Besançon (FR). **SABARIA, Patrick** [US/US]; 18, Chemin des Hauts de Grisy, F-78860 Saint-Nom-La-Bretèche (US). **SHARKAWI, Tahmer** [FR/FR]; 1 bis, rue Saint Hubery, F-34430 Saint-Jean-De-Vedas (FR). **VERT, Michel** [FR/FR]; 8, rue du Maréchal-Lefèvre, F-34170 Castelnau-le-Lez (FR).

(74) Agent: **CABINET HIRSCH**; 58, avenue Marceau, 75008 Paris (FR).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

(54) Title: **POLYMER-BASED STENT ASSEMBLY**

(57) Abstract: Methods for preparing a polymer-based stent assembly comprising an inflatable balloon catheter and a polymer-based stent resistant to relaxation-related negative recoil are provided. The methods comprise heating a polymeric cylindrical device which is at a final predetermined shape and diameter to a temperature sufficiently above the glass transition temperature (T<sub>g</sub>) of the polymer and for a time sufficient to erase any memory of previous processing of the polymeric cylindrical device and then quenching the polymeric cylindrical device to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter and shape, mounting the educated cylindrical device on an inflatable balloon catheter, reducing the diameter of the educated cylindrical device by heating to a temperature at or slightly above the T<sub>g</sub> of the polymer while evenly applying pressure on the exterior surface of the wall of the cylindrical device, and then cooling the cylindrical device below the T<sub>g</sub> of the polymer to provide a stent assembly comprising an inflatable balloon catheter and an expandable, educated, polymeric stent snugly and stably disposed thereon. Assemblies comprising an inflatable balloon and a polymer based stent that is substantially resistant to relaxation related recoil mounted snugly on the balloon are also provided.

WO 2005/096992 A1

## POLYMER-BASED STENT ASSEMBLY

### FIELD OF THE INVENTION

[0001] The present invention relates to a polymer-based stent assembly comprising an inflatable balloon catheter and a polymer-based stent for maintaining the shape of a tube, duct, or vessel, including, but not limited to, a urethral duct, a biliary duct, a blood vessel, a lymph vessel, a bronchial tube, or a duct in the prostate of a mammalian subject, preferably a human subject. More particularly, the present invention relates to an assembly comprising a degradable polymeric stent that exhibits little to no relaxation-related negative recoil when implanted in a tube, duct or vessel of a mammalian subject.

### BACKGROUND

[0002] Atherosclerosis is a disease in which vascular lesions or plaques consisting of cholesterol crystals, necrotic cells, lipid pools, excess fiber elements and calcium deposits accumulate on the interior walls of an individual's arteries. The presence of such plaques in the artery leads to thickening of the arterial wall and narrowing of the lumen. Eventually the enlargement of such plaques can lead to an occlusion of the lumen of the artery at the site of the lesion. One of the most successful procedures for treating atherosclerosis of the coronary arteries is percutaneous transluminal coronary angioplasty, hereinafter referred to as "PTC angioplasty". PTC angioplasty consists of introducing a deflated balloon into the lumen of the atherosclerotic artery, placing the balloon adjacent the site of the plaque or atherosclerotic lesion, inflating the balloon to a pressure of approximately 6 to 20 atmospheres thereby "cracking" the plaque and increasing the cross-sectional area of the lumen of the artery.

[0003] Unfortunately, the pressure that is exerted on the plaque during PTC angioplasty also traumatizes the artery. Accordingly, in 30-40% of the cases the vessel either gradually renarrows or recloses at the locus of the original stenotic lesion. This gradual renarrowing or reclosure, which is hereinafter referred to as "chronic restenosis," is a phenomenon that occurs almost exclusively during the first three to six months following angioplasty. Studies of the mechanism of chronic restenosis have shown that it is due in large part to a chronic constriction of the artery at the site of the barotraumatization, hereinafter referred to as the "retractile form of restenosis", and to a lesser extent to a

proliferation of smooth muscle cells, hereinafter referred to as the “proliferative form of restenosis”. Lafont et al. (1995) Restenosis After Experimental Angioplasty, *Circulation Res.* 76:996-1002.

[0004] A number of approaches for preventing restenosis are currently being used or tested. One approach involves the use of bioactive agents to prevent proliferation of the smooth muscle cells. To date, the use of bioactive agents alone has proven to be unsuccessful. Another approach employs a metallic stent which is deployed at the site of the stenotic lesion following PTC angioplasty. Although metallic stents have the mechanical strength necessary to prevent the retractile form of restenosis, their presence in the artery can lead to biological problems including vasospasm, compliance mismatch, and even occlusion. Occasionally, technical difficulties, including distal migration and incomplete expansion, have also been observed with metallic stents. Moreover, there are inherent, significant risks from having a metal stent permanently implanted in the artery, including erosion of the vessel wall. In addition, the constant exposure of the stent to the blood can lead to thrombus formation within the blood vessel.

[0005] Stents made from degradable polymers have also been suggested for preventing restenosis. Although, generally an attractive alternative to metallic stents, testing in animals has shown that degradable stents still suffer from multiple complications, including relaxation-related negative recoil and distal migration of the entire stent or portions thereof and formation of an occlusive thrombus within the lumen of the stent.

[0006] Accordingly, it is desirable to have a new stent that overcomes the disadvantages of the current stent designs. A polymer-based stent that exhibits little to no relaxation-related negative recoil when implanted in the blood vessel or duct of a mammalian subject is desirable. It is also desirable to have a stent assembly comprising an inflatable balloon catheter and a degradable polymeric stent that is stably and snugly disposed thereon. A polymer-based stent assembly that does not require a mechanical restraint to prevent the stent from expanding when stored at room temperature or when exposed to the physiological conditions found in the bloodstream of a human patient are especially desirable. Methods of preparing such stents and stent assemblies are also desirable.

### SUMMARY OF THE PRESENT INVENTION

[0007] The present invention provides methods for preparing a polymer-based stent assembly comprising an inflatable balloon catheter and a polymer-based stent resistant to relaxation-related negative recoil when implanted in the lumen of a blood vessel or duct of a mammalian subject, particularly a human subject. The polymer-based stent is in the form of a hollow cylindrical device comprising a wall formed from a polymer, preferably a degradable and bioresorbable polymer. Such wall defines a first open end, a second open end, and a channel extending from the first to the second open end, and has incorporated therein open spaces or slits that allow for a reduction in diameter and an increase in diameter of the cylindrical device without substantially altering the thickness of the wall.

[0008] In one aspect, the method comprises heating a polymeric cylindrical device which is at a final predetermined shape (i.e., the final desired diameter, wall thickness, length, and design of the stent following expansion) to a temperature sufficiently above the glass transition temperature ( $T_g$ ) of the polymer and for a time sufficient to erase any memory of previous processing of the polymeric cylindrical device, and then quenching the polymeric cylindrical device, i.e., rapidly cooling the cylindrical device at a temperature below the  $T_g$  of the polymer, to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter and shape (a procedure referred to hereinafter as “educating the cylindrical device”). Preferably, the polymeric cylindrical device is mounted on and in contact with a support during such education procedure. Thereafter, the method comprises mounting the educated cylindrical device on an inflatable balloon catheter, reducing the diameter of the educated cylindrical device by heating to a temperature at or slightly above the  $T_g$  of the polymer while evenly applying pressure on the exterior surface of the wall of the cylindrical device (a step referred to hereinafter as “crimping the cylindrical device”), and then cooling the cylindrical device below the  $T_g$  of the polymer to provide a stent assembly comprising an inflatable balloon catheter and an expandable, educated, polymeric stent snugly and stably disposed thereon. Slits or open spaces which allow for a reduction in diameter of the cylindrical device without substantially altering the wall thickness during crimping are incorporated into the cylindrical device prior to the time the cylindrical device is crimped on the inflatable balloon catheter. The temperature at which the cylindrical device is heated during crimping is high enough to allow reduction in diameter of the cylindrical device but low enough to not erase the memory of the final predetermined shape and

diameter of the educated cylindrical device. Thus, the temperature at which the educated cylindrical device is heated during crimping is less than the temperature at which the cylindrical device is heated during education of the cylindrical device. In addition, the time during which the cylindrical device is heated during crimping is less than the time during which the cylindrical device is heated during education of the cylindrical device. In accordance with the present method, expansion of the polymeric stent to its final predetermined shape can be achieved either by inflating the balloon catheter on which the polymeric stent is disposed at body temperature, or by inflating the balloon catheter on which the polymeric stent is disposed while heating the stent to a temperature close to but not above the Tg of the polymer.

[0009] In another aspect, the method of the present invention starts with a polymeric tube whose diameter initially is less than the final predetermined diameter. Such tube, which also has slits or open spaces in the wall to allow expansion of the tube without substantially altering the diameter of the tube is first heated to a temperature close to or above the Tg of the polymer and expanded to provide a cylindrical device whose diameter is equal to the final desired diameter. Thereafter the cylindrical device is educated as described above to provide an educated cylindrical device having a memory of the final predetermined shape and diameter, and then crimped on a balloon catheter as described above to provide an assembly comprising the balloon catheter and an expandable, educated, polymeric stent snugly and stably disposed thereon.

[0010] The present invention also provides an assembly comprising an inflatable balloon catheter and a polymeric stent prepared in accordance with the present method.

[0011] In another aspect, the present invention relates to an assembly comprising an inflatable balloon catheter and a polymer-based stent mounted thereon. The stent is a cylindrical device formed from a degradable and bioresorbable polymeric material having a Tg at least 8 degrees greater than 37°C, preferably more than 20 degrees C above 37°C, more preferably from about 45 to about 120 degrees C. The cylindrical device comprises a wall defining a first open end, a second open end, and a channel extending from the first open end to the second open end. The wall has voids or open spaces incorporated therein that allow the cylindrical device to be expanded to a larger diameter and substantially the same wall thickness when the balloon catheter is inflated or when the cylindrical device is heated to a temperature above the Tg of the polymer. Advantageously, the stent of the present invention

exhibits little to no relaxation-related negative recoil when deployed in the blood vessel of a subject or when expanded to the final predetermined shape and diameter and stored at 37°C for 4-6 weeks or more. Advantageously, the assembly of the present invention has a diameter which allows it to be easily inserted into a blood vessel of the subject and advanced to a target site. Advantageously, the stent of the present invention exhibits expansion (positive recoil) and adaptation to the geometry of the artery when the stent is not fully deployed up to its final diameter during deployment. In addition, the stent of the present invention is stably disposed on the balloon, meaning that a mechanical restraint is not required to prevent the stent from rapidly expanding to its final diameter during storage at room temperature. Thus, although not required, the assembly of the present invention, optionally, also comprises a retractable sheath covering the exterior surface of the stent. Such sheath serves to prevent deformation of the stent and slow expansion during storage.

[0012] The present invention also relates to methods of making stents lacking a memory of previous processing and having a memory of a final predetermined shape and diameter, and to stents made by such methods. Such stents exhibit little to no relaxation-related recoil when implanted in the lumen of a duct, vessel, or tube of a mammalian subject.

[0013] The present invention also relates to a method of reducing the risk of chronic restenosis that can occur in an artery of a patient following PTC angioplasty. The method employs the assembly of the present invention. The method comprises delivering the stent assembly of the present invention to the locus of a stenotic lesion; inflating the balloon catheter to expand the stent to a diameter equal to or less than the final predetermined diameter such that the stent contacts or slowly expands to contact the interior walls of the blood vessel at the locus of the stenotic lesion; and then deflating and withdrawing the balloon catheter. In accordance with the present invention, it has been determined that a stent of the present invention which is not fully expanded to the final predetermined diameter by inflation of the balloon catheter will continue to expand following withdrawal of the balloon and thereby support the interior wall of the blood vessel. Because the stent of the present invention has been educated to have a memory of the final desired diameter, it exhibits little to no negative recoil following implantation into the target site.

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions:

[0014] “Bioresorbable polymer” as used herein refers to a polymer whose degradation by-products can be bio-assimilated or excreted via natural pathways in a human body.

[0015] “Crimping” as used herein refers to a process that involves radial pressing on a polymeric cylindrical device having slits, or openings in the wall thereof in order to allow a decrease in the diameter of the device without substantially affecting the thickness of the wall or struts of the cylindrical device. Such process, typically also results in an increase in length of the cylindrical device.

[0016] “Degradable polymer” as used herein refers to a polymer that breaks down into monomers and oligomers when placed in a human body or in an aqueous solution and maintained under conditions of temperature, osmolality, pH, etc., that mimic physiological media preferably without involving enzymatic degradation in order to minimize the risk of triggering the antigenantibody defense system of the human body.

[0017] “Final predetermined shape and diameter” as used herein refers to the desired diameter, length, design and wall thickness of a stent that has been deployed to a target site in a vessel, particularly a blood vessel, duct, or tube in a mammalian subject, particularly a human subject.

[0018] “Negative recoil” as used herein refers to an undesirable decrease in diameter of an expanded stent.

[0019] “Positive recoil” as used herein refers to an increase in diameter of a stent that has been educated to have a desired final diameter but has not been fully expanded to the desired final diameter.

[0020] “Relaxation-related recoil” as used herein refers to the slow change in dimensions of a polymeric device due to a time-dependent slow rearrangement of molecule conformations according to a well known behavior of viscoelastic polymeric matters. Such rearrangement is due to thermal agitation that slowly leads the polymeric material to a thermodynamic equilibrium typical of the storage conditions when it has been processed

under different environmental conditions. Relaxation is very slow below  $T_g$ , i.e. when the matter is in the glassy state.

[0021] “ $T_g$ ” or “glass transition temperature” as used herein refers to the temperature at which a polymer changes from a rubbery state to a glassy state and vice versa.

[0022] In one aspect the present invention provides an assembly which can be used to deliver a polymer-based stent to a region in the lumen of a tube, duct, or vessel of a mammalian subject, particularly a human subject. The assembly comprises an inflatable balloon catheter and a polymeric stent that when expanded to a final predetermined shape and diameter exhibits little to no negative recoil. Thus, the assembly is particularly useful for delivering the stent of the present invention to a lesion in the blood vessel of a human subject who has undergone PTC angioplasty.

[0023] The polymeric stent of the present invention is snugly mounted on the balloon catheter and has an internal diameter that matches the external diameter of the deflated balloon catheter, and is less than the final predetermined diameter so that the stent assembly can be easily inserted and passed through a tube, vessel or duct of the subject. The polymeric stent of the present invention is stably disposed on the balloon catheter such that the stent does not expand when stored at room temperature or when inserted into the blood vessel of a mammalian subject, particularly a human subject. Although not necessary, the present assembly also, optionally, comprises a retractable sheath disposed on the exterior surface of the polymeric stent.

#### I. Stent

[0024] The stent of the present assembly is formed from a degradable and bioresorbable polymer having a  $T_g$  at least 8 degrees above  $37^\circ\text{C}$ , preferably at least 20 degrees above  $37^\circ\text{C}$ . The polymer that forms the walls of the stent can be a homopolymer or a copolymer. Preferably, the polymer is totally amorphous in order to minimize the risk of formation of tiny inflammatory crystalline residues during degradation. The chains of the polymer are not cross-linked. However, light cross-linking is acceptable provided that thermal and viscoelastic characteristics that allow education, crimping, and deployment of the device are maintained. In certain embodiments, the polymer has a  $T_g$  of from about  $45^\circ\text{C}$  to about  $120^\circ\text{C}$ . Examples of the types of polymers that are suitable for the stent of the present invention include, but are not limited to, lactic acid-based stereocopolymers (PLAx

copolymers composed of L and D units, where X is the percentage of L-lactyl units) ( $55 < T_g < 60$ ), copolymers of lactic and glycolic acids (PLA<sub>x</sub>GA<sub>y</sub>, where X, the percentage of L-lactyl units, and Y, the percentage of glycolyl units, are such that the T<sub>g</sub> of the copolymer is above 45°C), and Poly(lactic-co-glycolic-co-gluconic acid) where the OH groups of the gluconyl units can be more or less substituted (PLA<sub>x</sub>GA<sub>y</sub>GL<sub>z</sub>, where X, the percentage of L-lactyl units, and Y, the percentage of glycolyl units, and Z the percentage of gluconyl units are such that the T<sub>g</sub> of the terpolymer is above 45°C). Other suitable polymers include, but are not limited to, polylactic acid (PLA), polyglycolic acid (PGA) polyglactin (PLAGA copolymer), polyglyconate (copolymer of trimethylene carbonate and glycolide, and a copolymer of polyglycolide or lactide acid or polylactic acid with .epsilon.-caprolactone), provided that the polymer has a T<sub>g</sub> of at least 45°C or greater.

[0025] The stent of the present assembly is a cylindrical device having a first open end, a second open end, a channel connecting the first and second open ends, and slits, or openings in the walls of the cylindrical device. Such slits or openings allow crimping of the polymeric cylindrical device from a larger diameter to a smaller diameter without substantially altering the thickness of the wall of the device, as well as expansion of the polymeric cylindrical device from a smaller diameter, e.g. the crimped diameter, to a larger diameter without substantially altering the thickness of the wall upon inflation of a balloon catheter that is disposed inside the cylindrical device. Such slits or openings may be formed by standard processing techniques such as by molding, cutting, engraving or photolithography.

[0026] The polymeric cylindrical device is formed by standard techniques such as extrusion, molding, spinning, injection molding or any other processing technique that transforms the brut polymer into a hollow cylindrical device. Although less desirable, the cylindrical device can also be formed by knitting polymer threads or fibers, provided that the stitches are then fused together to form a continuous polymeric network in which the slits, or openings are formed by the voids between the stitches. The initial polymeric cylindrical device that is formed by any of these processes can be configured to have the final predetermined shape, length, wall thickness and diameter, all of which are tailored to the application for which the stent is to be utilized. For example, for cardiovascular applications the initial polymeric device that is formed by these processes can have a final predetermined length ranging from 0.5 cm to approximately 3 cm. For certain applications, the initial

polymeric cylindrical device can have a final, predetermined diameter ranging from 0.50 mm to 8.0 mm with a final, predetermined wall thickness ranging from 0.05 to 0.5 mm. Alternatively, the initial cylindrical device that is formed by any of these processes can have a smaller diameter than the final predetermined diameter.

[0027] Stents of the present invention can be formulated so as to be able to carry and deliver a variety of materials or bioactive agents, provided that these materials or agents do not form a solid solution with the polymer and do not act as a plasticizer that decreases the Tg of the polymeric device below 45°C. Such materials include, but are not limited to, opacifying agents, natural agents, and pharmaceutical agents. The polymer can be admixed with such materials or agents. For example, the material or bioactive agent may be incorporated into the polymeric cylindrical device as a solid dispersion in a matrix. The matrix can be formed with a dispersion of uniform particles in the biocompatible polymeric materials of the type hereinbefore described in connection with the stent of the present invention. Such particles must be small enough not to affect the continuity of the matrix, e.g., one fifth to one tenth the strut or wall thickness of the cylindrical device. The materials or bioactive agents may also be deposited on the exterior or interior surface of the cylindrical device either by impacting or chemical coupling.

[0028] Stents of the present invention lack memory of previous processing and have a memory of the final predetermined shape and diameter.

## II. Preparation of the Polymer-Based Stent Assembly

[0029] In another aspect, the present invention relates to a method of preparing the present polymer-based stent and stent assembly. In those instances where the initial polymeric cylindrical device has a smaller diameter than the final predetermined diameter, slits or openings are formed in the cylindrical device as described above, and then the cylindrical device is deformed or expanded to the final shape and diameter. This can be achieved by inserting a balloon into the polymeric cylindrical device (referred to hereinafter as a "pre-cut cylindrical device"), heating the pre-cut cylindrical device to a temperature at or above the Tg of the polymer that is used to form the pre-cut cylindrical device, and inflating the balloon to a size approximately equal to or slightly greater than the final predetermined interior diameter of the implanted stent. While maintaining the expanded pre-cut cylindrical device at the final predetermined shape, size, and diameter, such as by mounting the pre-cut

cylindrical device on a solid support, the pre-cut cylindrical device is educated to erase any former process-related memory and to acquire a memory of the final predetermined shape, size and diameter. In those instances where the initial cylindrical device is formed at the final predetermined shape, size, and diameter, such deformation or expansion step is not required. In those instances where the initial cylindrical device is formed at the final predetermined shape, size, and diameter, slits or openings in the cylindrical device can be made prior to or after the education step as described below.

[0030] While it is at the final predetermined shape, size, and diameter, the cylindrical device is educated by heating the device to a temperature sufficiently above the  $T_g$  of the polymer from which the device is formed and for a time sufficient to erase any former process-related memory and to impart a new memory of the final predetermined shape and diameter to the polymeric cylindrical device. It is believed that such conditions allow the polymer chains to relax and reorganize themselves from an entanglement typical of the former processing stages to an entanglement typical of the high temperature at which the cylindrical device is educated. This last entanglement is frozen by quenching (fast cooling to room temperature or below). In those cases where the polymeric cylindrical device initially is at a diameter that is less than the final predetermined diameter, heating to a temperature well above the  $T_g$  of the polymer erases not only the anisotropic internal stresses promoted by the extrusion or molding process during which the polymeric chains are more or less oriented and quenched heterogeneously by contact with the cold atmosphere or the cold mold, but also the former processing-related memory of the polymer chains. Good results have been obtained by heating a laser-precut polymeric cylindrical device formed from PLA75 and deformed from a diameter of 1.0 mm to 4 mm at a temperature of 80°C for 30 minutes. It is expected that temperatures of from about 45°C to about 120°C and times of 5 minutes or more will be suitable for educating stents made from PLAx with  $0 < X < 100$ , PLAxGAy with  $0 < X < 25$  and  $75 < Y < 100$ , or any PLAxGAyGLz.

[0031] While still in its expanded state, the cylindrical device is then quenched or cooled to a temperature below the  $T_g$  of the polymer, preferably to room temperature, more preferably below room temperature. Such cooling step is performed at a rate sufficiently rapid to stiffen the cylindrical device into its new shape, and sufficiently slow to allow the whole polymer mass to reach equilibrium at a temperature below the  $T_g$  without chain

relaxation taking place. Given the thinness of the stent, this time is relatively short compared to the time during which the polymeric tube is educated.

[0032] The educated, polymeric cylindrical device is then mounted on a deflated balloon catheter and uniformly crimped to reduce its diameter and facilitate introduction of the stent assembly of the present invention into a vessel, duct, or tube of a mammalian subject, particularly a human subject. During crimping, the diameter of the cylindrical device is reduced by a suitable amount from the educated size, as for example by 100 to 400 percent. The crimping involves heating the educated cylindrical device to a temperature sufficient to allow deformation of the polymeric matrix without erasing the memory that has been imparted to the device during the education step. Thus, during crimping the educated cylindrical device is heated to a temperature at or slightly above the T<sub>g</sub> of the polymer, while evenly applying pressure to the exterior surface of the cylindrical device. Good results have been obtained by heating the cylindrical device to a temperature 5°C above the T<sub>g</sub> of the polymer. Such crimping step substantially uniformly reduces the diameter of the cylindrical device such that it fits snugly on the balloon. Simultaneously, the crimping step also increase the length of the cylindrical device provided that the design allows the compression of the slits, openings, or voids and the arrangement of the struts of the cylindrical device close to each other. To quench the polymer matrix of the cylindrical device, the stent assembly is then rapidly cooled to a temperature below the T<sub>g</sub> of the polymer, preferably to room temperature, more preferably to a temperature below room temperature, while maintaining pressure on the exterior surface of the cylindrical device. The final product is a stent assembly comprising an inflatable balloon catheter having a snug fitting polymeric stent stably disposed thereon. As used herein the phrase "stably disposed thereon" means that the stent will not expand under normal storage conditions, i.e., while stored at room temperature or below room temperature, or during the short period of time allowed to the clinician to insert the assembly into a vessel of a mammalian subject.

### III. Procedures for Determining Times and Temperatures for Educating and Crimping the Stent of the Present Invention.

[0033] Temperatures and times suitable for educating the cylindrical device and for thereby developing a stent resistant to relaxation-related recoil can be assessed by inflating the balloon catheter of the present stent assembly to the final predetermined diameter, removing the balloon catheter after deflation and storing the expanded stent at 37°C. If the

stent exhibits little to no recoil when stored under these conditions for 4 to 6 weeks or, preferably the time estimated for an artery wall to recover from PTC angioplasty, the times and temperatures employed for educating the stent are suitable. In those cases where the polymeric stent exhibits a small amount of recoil, the cylindrical device can be educated at a diameter slightly larger than the final predetermined diameter in order to compensate for the small amount of negative recoil.

[0034] Temperatures and times suitable for crimping the stent to a reduced diameter can be assessed by allowing the stent-mounted balloon catheter of the present assembly to stay at room temperature or at the storage temperature. If the crimped stent stays collapsed at the small diameter corresponding to the deflated balloon under these conditions, the times and temperatures employed during crimping are suitable.

#### IV. Deployment of the Stent.

[0035] The polymer-based stent assembly of the present invention is introduced into a duct, tube, or vessel, e.g., a blood vessel of a mammalian subject, preferably in conjunction with a guiding catheter, and advanced to a target site, e.g., the site of stenotic lesion. After it is located at the target site the balloon is rapidly inflated thereby causing expansion of the stent to its final desired diameter or slightly below its final diameter. Optionally, the inflation fluid, balloon and stent are heated to a temperature above body temperature to aid in expansion. During this process the diameter of the stent increases, but the thickness of the walls of the stent remain substantially the same.

#### EXAMPLES

[0036] The following examples contained herein are intended to illustrate but not limit the invention.

##### Example 1

[0037] A polymeric tube was formed from PLA75 (Mw of approximately 130,000, Mw/Mn = 1.8, as determined by Size Exclusion Chromatography, Tg approximately 58°C) by extrusion through a dye interior/exterior of 1.2/1.4 mm diameter. Slits were then cut into the extruded tube using a femtosecond pulsed laser according to a design permitting expansion of the small diameter polymeric cylindrical device without changing wall thickness. The small

diameter cylindrical device was mounted onto a deflated 4 mm balloon, heated to 65°C in a heating bath, and expanded to 4 mm by inflating the balloon. The resulting assembly was then rapidly cooled to about room temperature. The balloon was removed, and a 4 mm stainless steel support was inserted into the cylindrical device to lock the device into its final pre-determined diameter and shape. In order to erase any memory of previous processing and to impart a memory of this final diameter and shape to the cylindrical device, the device, mounted on the stainless steel support, was heated in an 80°C pre-heated oven for 30 minutes. Thereafter, the educated, cylindrical device was rapidly cooled to room temperature by inserting the device in running water at a temperature of 20°C, while the device was still mounted on the support. The cooling has an effect of stiffening the polymeric device. The newly shaped stent was then mounted on a new, deflated, balloon and both the balloon and the stent were then heated to 65°C, a temperature high enough to allow deformation of the device but not high enough to allow the chains to reorganize in a short period of time, and then the stent was crimped on the balloon by applying equal pressure to the exterior surface of the stent. The stent was crimped on the deflated balloon by using a standard system, which is typically used for the crimping of metallic stents. Such system applies equal radial pressure to the exterior surface of the device. Once the diameter was reduced to a size small enough to obtain a snug fit on the deflated balloon, the pressure was maintained while the contracted, mounted stent was rapidly cooled to stiffen the stent in the crimped shape and reduced diameter. This stiffening ensured a snug fit of the stent on the balloon.

#### Example 2

[0038] A polymeric tube was formed from PLA75 (Mw of approximately 130,000, Mw/Mn = 1.8, as determined by Size Exclusion Chromatography, Tg approximately 55°C) by extrusion through a dye interior/exterior of 4.0/4.2 mm diameter. Void spaces were then cut into the extruded tube using a femtosecond pulsed laser according to a design which permits contraction of the resulting educated, polymeric cylindrical device to a smaller diameter without modifying wall thickness. A 4 mm stainless steel support was inserted into the cylindrical device to lock the device into the final desired diameter and shape. In order to erase any memory of previous processing and to impart a memory of this final diameter and shape to the cylindrical device, the device, mounted on the stainless steel support, was heated in an 80°C pre-heated oven for 30 minutes. Thereafter, the educated, cylindrical device was rapidly cooled to room temperature by inserting the device in running water at a temperature

of 20°C, while the device was still mounted on the support. The cooling has an effect of stiffening the polymer device. The educated stent was then mounted on a new, deflated, balloon and both the balloon and the stent were then heated to 65°C, a temperature sufficiently high to allow deformation of the device but not high enough to allow the chains to reorganize. The stent was then crimped on the balloon by applying equal pressure to the exterior surface of the stent. Once the diameter of the stent was reduced to a size small enough to obtain a snug fit on the deflated balloon, the pressure was maintained while the contracted, mounted stent was rapidly cooled to stiffen the stent in the crimped shape and reduce diameter. This stiffening ensured a snug fit of the stent on the balloon.

#### Example 3

[0039] A polymeric tube was formed from PLA50 (Mw of approximately 145,000, Mw/Mn = 1.6, as determined by Size Exclusion Chromatography, Tg approximately 58°C) by extrusion through a dye interior/exterior of 1.2/1.4 mm diameter. The tube was processed as described above in example 1 to provide a stent assembly of the present invention.

#### Example 4

[0040] A polymeric tube was formed from PLA50 (Mw of approximately 145,000, Mw/Mn = 1.6, as determined by Size Exclusion Chromatography, Tg approximately 55°C) by extrusion through a dye interior/exterior of 4.0/4.2 mm diameter. The tube was processed as described above in example 2 to provide a stent assembly of the present invention.

#### Example 5

[0041] A polymeric tube was formed from PLA62.5 (Mw of approximately 165,000, Mw/Mn = 1.7, as determined by Size Exclusion Chromatography, Tg approximately 56°C) by extrusion through a dye interior/exterior of 1.2/1.4 mm diameter. The tube was processed as described above in example 1 to provide a stent assembly of the present invention.

#### Example 6

[0042] A polymeric tube was formed from PLA62.5 (Mw of approximately 165,000, Mw/Mn = 1.7, as determined by Size Exclusion Chromatography, Tg approximately 56°C) by extrusion through a dye interior/exterior of 4.0/4.2 mm diameter. The tube was processed as described above in example 2 to provide a stent assembly of the present invention.

Example 7

[0043] A polymeric tube was formed from PLA96GA4 (Mw of approximately 185,000, Mw/Mn = 1.8, as determined by Size Exclusion Chromatography, Tg approximately 51°C) by extrusion through a dye interior/exterior of 1.2/1.4 mm diameter. The tube was processed as described above in example 1 to provide a stent assembly of the present invention.

Example 8

[0044] A polymeric tube was formed from PLA96GA4 (Mw of approximately 185,000, Mw/Mn = 1.8, as determined by Size Exclusion Chromatography, Tg approximately 51°C.) by extrusion through a dye interior/exterior of 4.0/4.2 mm diameter. The tube was processed as described above in example 2 to provide a stent assembly of the present invention.

[0045] Stents made as described in examples 1-8 were expanded to the final predetermined diameter and stored at room temperature in a liquid environment for more than 3 months did not exhibit negative recoil.

[0046] From the foregoing it can be seen that there has been provided a stent, an assembly comprising an inflatable balloon and the present stent, and a method for use thereof which has numerous advantages. Because the present stent has a memory of a final predetermined shape and diameter, it exhibits little to no relaxation-related recoil when implanted into a vessel of a mammalian subject. Moreover, when expanded by mechanical stress to a diameter less than the final predetermined diameter, the present stent may exhibit positive recoil and adaptation to the geometry of the vessel in which it is deployed. The stents of the present invention can be formulated and/or treated so as to carry materials and bioactive agents to the target site.

## CLAIMS

What is claimed is:

1. A method for preparing an assembly for delivering a degradable and bioresorbable polymeric stent that is resistant to relaxation-related recoil to a mammalian subject, comprising:

(a) heating a polymeric cylindrical device which is at a final predetermined radial diameter and wall thickness to a temperature sufficiently above the glass transition temperature ( $T_g$ ) of the polymer and for a time sufficient to erase memory of previous processing of the polymeric device, wherein the polymeric cylindrical device has a wall defining a first open end, a second open end, and a channel connecting the first and the second open end;

(b) rapidly cooling the polymeric cylindrical device at a temperature below the  $T_g$  of the polymer to quench the polymeric cylindrical device and to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter and shape;

(c) forming slits, voids, or open spaces in the wall of the polymeric cylindrical device prior to step (a) or after step (b), wherein the slits, voids, or open spaces are configured to allow a reduction in diameter of the device without substantially altering the wall thickness of the device;

(d) mounting the educated polymeric cylindrical device on an inflatable balloon catheter;

(e) reducing the diameter of the cylindrical device by heating the cylindrical device to a temperature at or slightly above the  $T_g$  of the polymer while evenly applying pressure on the exterior surface of the wall of the cylindrical device; and

(f) then rapidly cooling the cylindrical device below the  $T_g$  of the polymer to provide an assembly comprising an inflatable balloon catheter and an expandable polymeric stent which is substantially resistant to relaxation-related recoil when implanted in the lumen of a tube, duct, or vessel of the mammalian subject or when expanded and stored at 37° C for 4 to 6 weeks.

2. The method of claim 1 wherein the cylindrical device is mounted on a support for maintaining the diameter and shape of the device during step (a) and step (b) .
3. The method of claim 1 wherein the stent is formed from a polymer selected from PLA and stereocopolymers (copolymers composed of L and D units), PLAGA, Poly(lactic-co-glycolic-co-gluconic acid).
4. The method of claim 1 wherein the cylindrical device is reduced to a diameter that is less than the diameter of the lumen of the target duct, tube, or vessel during step (e).
5. The method of claim 1 wherein the wall thickness of the cylindrical device is substantially the same before and after step (e).
6. A method for preparing an assembly for delivering a degradable and bioresorbable polymeric stent into the lumen of a tube, duct, or vessel of a mammalian subject, comprising:
  - (a) providing a polymeric cylindrical device comprising a wall defining a first open end, a second open end, and a channel connecting said first open end and said second open end, wherein the cylindrical device has a diameter and wall thickness comparable to the final desired diameter and wall thickness of the stent;
  - (b) educating the device by erasing memory of previous processing of the polymeric device and establishing a memory of the desired diameter; wherein such education is achieved by heating the device to a temperature at least 8 degrees C above the Tg of the polymer;
  - (c) quenching the device to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter and shape;
  - (d) forming slits, voids, or open spaces in the wall of the polymeric cylindrical device before or after the device is educated;
  - (e) mounting the educated polymeric cylindrical device on an inflatable balloon catheter;
  - (f) crimping the cylindrical device on the inflatable balloon catheter while heating the cylindrical device to a temperature at or slightly above the Tg of the polymer; and

(g) then rapidly cooling the cylindrical device below the  $T_g$  of the polymer to provide an assembly comprising an inflatable balloon catheter and an expandable polymeric stent which is substantially resistant to relaxation-related recoil when implanted in the lumen of a tube, duct, or vessel of a mammalian subject or when expanded to a final predetermined shape and diameter and stored at 37°C for 4 weeks or more.

7. A method for preparing an assembly for delivering a degradable and bioresorbable polymeric stent into the lumen of a tube, duct, or vessel of a mammalian subject, comprising:

(a) providing a hollow, cylindrical device comprising a wall having slits, openings, or voids therein, wherein the hollow cylindrical device has a radial diameter that is less than the final predetermined diameter of the stent;

(b) heating the polymeric cylindrical device to a temperature close to or above the  $T_g$  of the polymer while expanding the tube to the final predetermined diameter;

(c) mounting the cylindrical device on a support for maintaining the cylindrical device at the final predetermined diameter;

(d) heating the mounted cylindrical device to a temperature sufficiently above the glass transition temperature ( $T_g$ ) of the polymer and for a time sufficient to erase memory of previous processing of the polymeric device;

(e) rapidly cooling the polymeric cylindrical device at a temperature below the  $T_g$  of the polymer to quench the polymeric cylindrical device and to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter;

(f) mounting the educated polymeric cylindrical device on an inflatable balloon catheter;

(g) reducing the diameter of the cylindrical device by heating the cylindrical device to a temperature at or slightly above the  $T_g$  of the polymer while evenly applying pressure on the exterior surface of the wall of the cylindrical device; and

(h) then rapidly cooling the cylindrical device below the  $T_g$  of the polymer to provide an assembly comprising a inflatable balloon catheter and an expandable polymeric stent which is substantially resistant to relaxation-related recoil when implanted in the lumen

of a tube, duct, or vessel of a mammalian subject or when expanded to a final predetermined shape and diameter and stored at 37°C for 4 weeks or more.

8. The method of claim 6 wherein the stent is formed from a polymer selected from PLA and stereocopolymers (copolymers composed of L and D units), PLAGA, Poly(lactic-co-glycolic-co-gluconic acid).

9. The method of claim 6 wherein the wall thickness of the cylindrical device is substantially the same before and after step (g).

10. A method for preparing an assembly for delivering a degradable and bioresorbable polymeric stent into the lumen of a tube, duct, or vessel of a mammalian subject, comprising:

(a) providing a polymeric cylindrical device comprising a wall defining a first open end, a second open end, and a channel connecting said first open end and said second open end, and having slits, voids, or open spaces for permitting expansion and contraction of the device without substantially altering the thickness of the wall, wherein the cylindrical device has a radial diameter that is less than the final desired diameter of the stent,

(b) expanding the polymeric device to the final desired diameter while heating to a temperature close to or above the Tg of the polymer;

(c) educating the device by erasing memory of previous processing of the polymeric device and establishing a memory of the desired diameter; wherein such education is achieved by heating the device, which is mounted on a support, to a temperature at least 8 degrees C above the Tg of the polymer;

(c) quenching the device to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter and shape;

(d) mounting the educated polymeric cylindrical device on an inflatable balloon catheter;

(e) crimping the cylindrical device on the inflatable balloon catheter while heating the cylindrical device to a temperature at or slightly above the Tg of the polymer; and

(f) then rapidly cooling the cylindrical device below the Tg of the polymer to provide an assembly comprising a inflatable balloon catheter and an expandable polymeric

stent which is substantially resistant to relaxation-related recoil when implanted in the lumen of a tube, duct, or vessel of a mammalian subject or when expanded to a final predetermined shape and diameter and stored at 37°C for 4 weeks or more.

11. An assembly comprising an inflatable balloon and a polymeric stent prepared in accordance with the method of claim 1, 6, 7, or 10.

12. An assembly for introducing a degradable and bioresorbable stent into a vessel, tube, or duct of a mammalian subject, comprising:

an inflatable balloon catheter, and

a stent formed from a degradable polymeric material having a T<sub>g</sub> at least 45° mounted thereon,

wherein the stent comprises a wall defining a first open end, a second open end, and a channel connecting the first and second open end, and wherein the wall of stent includes voids, open spaces, or slits that allow the stent to be expanded to a larger diameter, a shorter length, and the same wall thickness when the balloon catheter is inflated or when the stent is heated to a temperature above the T<sub>g</sub> of the polymer, and

wherein the stent exhibits little to no negative recoil when deployed in the blood vessel of a subject or when expanded to a final predetermined shape and diameter and stored at 37°C for 4 weeks or more; and

wherein the assembly has a diameter that allows it to be inserted into a tube, vessel or duct of the subject and advanced to a target site.

13. The assembly of claim 12, wherein the assembly has a diameter that allows the stent to be inserted into a blood vessel of a human subject and advanced to stenotic lesion.

14. The assembly of claim 12 wherein the stent exhibits positive recoil and adaptation to the geometry of the artery when the stent is not fully deployed up to its final diameter during deployment.

15. The assembly of claim 12 wherein the stent is formed from a polymer selected from PLA and stereocopolymers (copolymers composed of L and D units), PLAGA, Poly(lactic-co-glycolic-co-gluconic acid).

16. The assembly of claim 12 wherein the stent is stably mounted on the balloon.
17. The assembly of claim 12 further comprising a retractable sheath covering the exterior surface of the stent.
18. The assembly of claim 12 wherein bioactive agent or tracking agent is disposed within or on a surface of the stent.
19. A method for preparing a degradable and bioresorbable polymeric stent for implantation into the lumen of a tube, duct, or vessel of a mammalian subject, comprising:
  - (a) heating a polymeric cylindrical device which is at a final predetermined radial diameter and wall thickness to a temperature sufficiently above the glass transition temperature ( $T_g$ ) of the polymer and for a time sufficient to erase memory of previous processing of the polymeric device, wherein the polymeric cylindrical device has a wall defining a first open end, a second open end, and a channel connecting the first and the second open end;
  - (b) rapidly cooling the polymeric cylindrical device at a temperature below the  $T_g$  of the polymer to quench the polymeric cylindrical device and to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter and shape; and
  - (c) forming slits, voids, or open spaces in the wall of the polymeric cylindrical device prior to step (a) or after step (b),wherein the stent is resistant to relaxation-related recoil when deployed in the blood vessel of a subject or when expanded to a final predetermined shape and diameter and stored at 37°C for 4 weeks or more.
20. The method of claim 19 wherein the cylindrical device is mounted on a support for maintaining the diameter and shape of the device during step (a) and step (b) .
21. The method of claim 19 wherein the stent is formed from a polymer selected from PLA and stereocopolymers (copolymers composed of L and D units), PLAGA, Poly(lactic-co-glycolic-co-gluconic acid).

22. A method for preparing a degradable and bioresorbable polymeric stent that is resistant to relaxation-related recoil when implanted into the lumen of a tube, duct, or vessel of a mammalian subject or when expanded to a final predetermined shape and diameter and stored at 37°C for 4 weeks or more, comprising:

(a) providing a hollow, cylindrical device comprising a wall having slits, openings, or voids therein, wherein the hollow cylindrical device has a radial diameter that is less than the final predetermined diameter of the stent;

(b) heating the polymeric cylindrical device to a temperature close to or above the  $T_g$  of the polymer while expanding the tube to the final predetermined diameter;

(c) mounting the cylindrical device on a support for maintaining the cylindrical device at the final predetermined diameter;

(d) heating the mounted cylindrical device to a temperature sufficiently above the glass transition temperature ( $T_g$ ) of the polymer and for a time sufficient to erase memory of previous processing of the polymeric device; and

(e) rapidly cooling the polymeric cylindrical device at a temperature below the  $T_g$  of the polymer to quench the polymeric cylindrical device and to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter.

23. The method of claim 22 wherein the stent is formed from a polymer selected from PLA and stereocopolymers (copolymers composed of L and D units), PLAGA, Poly(lactic-co-glycolic-co-gluconic acid).

24. A stent made in accordance with the methods of claims 19 or 22.

25. A stent substantially resistant to relaxation-related recoil when implanted in the lumen of a duct, vessel, or tube of a mammalian subject recoil or when expanded to a final predetermined shape and diameter and stored at 37°C for 4 weeks or more,

wherein said stent is formed from a polymer has a  $T_g$  of 45°C or greater, and

wherein said stent lacks a memory of processing, and has a memory of a final predetermined shape and diameter.

26. A method of reducing the risk of chronic restenosis that can occur in an artery of a patient following PTC angioplasty, comprising:

delivering the assembly of claim 12 to the locus of a stenotic lesion;

inflating the balloon to expand the stent to a diameter equal to or less than the final predetermined diameter; and

deflating and withdrawing the balloon.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/004133

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)  
EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/034940 A (SCIMED LIFE SYSTEMS INC) 1 May 2003 (2003-05-01) claim 1; figures 3,4	1-26
A	EP 0 809 981 A (BIOENGINEERED MATERIALS INC ; GEN VASCULAR DEVICES LTD (US)) 3 December 1997 (1997-12-03) claim 4	1-26
A	US 5 607 467 A (FROIX MICHAEL) 4 March 1997 (1997-03-04) column 10, lines 33-44 column 3, lines 4,5; claim 1	1-26

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

15 December 2004

Date of mailing of the international search report

30/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Dupuis, J-L

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/004133

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03034940	A	01-05-2003	US	2003083732 A1	01-05-2003
			EP	1437983 A2	21-07-2004
			WO	03034940 A2	01-05-2003
EP 0809981	A	03-12-1997	US	5670161 A	23-09-1997
			EP	0809981 A1	03-12-1997
US 5607467	A	04-03-1997	US	5258020 A	02-11-1993
			US	5163952 A	17-11-1992
			US	6248129 B1	19-06-2001

**Box No. VIII (i) DECLARATION: IDENTITY OF THE INVENTOR**

*The declaration must conform to the standardized wording provided for in Section 211; see Notes to Boxes Nos. VIII, VIII (i) to (v) (in general) and the specific Notes to Box No. VIII (i). If this Box is not used, this sheet should not be included in the request.*

Declaration as to the identity of the inventor (Rules 4.17(i) and 51bis.1(a)(i)):

in relation to this international application,

**Antoine LAFONT, 46, rue du Bac, 75007 Paris, FRANCE**

**Serge PIRANDA STATICE SANTE, Z.I. des Tilleroyes, 9, rue Thomas Edison, FR**

**Patrick SABARIA; 18, Chemin des Hauts de Grisy, 78860 Saint Nom La Breteche, FRANCE**

**Tahmer SHARKAWI, 1 bis, rue Saint Hubery, 34430 Saint Jean De Vedas, FRANCE**

**Michel VERT, 8, rue du Maréchal Lefebvre, 34170 Castelnau-Le-Lez, FRANCE**

**are the inventors of the subject matter for which protection is sought by way of this international application.**

this declaration is made for the purpose of: **all designations**

**Box No. VIII (iv) DECLARATION: INVENTORSHIP** (only for the purposes of the designation of the United States of America)  
*The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VIII, VIII (i) to (v) (in general) and the specific Notes to Box No. VIII (iv). If this Box is not used, this sheet should not be included in the request.*

**Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv))  
 for the purposes of the designation of the United States of America:**

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This declaration is directed to international application No. PCT/FR04/00833 (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Applications," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications: none

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Name: Antoine LAFONT

Residence: Paris, FR

(city and either US state, if applicable, or country)

Mailing Address: 46, rue du Bac, 75007 Paris, France

Citizenship: FR

Inventor's Signature:   
 (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)

Date: 22/04/04  
 (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)


Name: Serge PIRANDA STATICE SANTE

Residence: Besançon, FR

(city and either US state, if applicable, or country)

Mailing Address: Z.I. des Tilleroyes, 9 rue Thomas Edison, 25000 Besançon, France

Citizenship: FR

Inventor's Signature:   
 (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)

Date: 29/04/04  
 (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

☒ This declaration is continued on the following sheet, "Continuation of Box No. VIII (iv)".

**Continuation of Box No. VIII (i) to (v) DECLARATION**

*If the space is insufficient in any of Boxes Nos. VIII (i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII ..." (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.*

Continuation of box No. VIII.iv) :

Name : **Patrick SABARIA**

Residence : **Saint Nom La Breteche, FR**  
(city and either US State, if applicable, or country)

Mailing address : **18, Chemin des Hauts de Grisy, 78860 Saint Nom La Breteche, FR**

Citizenship : **FR**

Inventor's Signature : .....

Date : **22/4/2004** .....

Name : **Tahmer SHARKAWI**

Residence : **Saint Jean De Vedas, FR**  
(city and either US State, if applicable, or country)

Mailing address : **1 bis, rue Saint Hubery, 34430 Saint Jean De Vedas, France**

Citizenship : **CAN**

Inventor's Signature : .....

Date : **26/04/2004** .....

Name : **Michel VERT**

Residence : **Castelnau-Le-Lez, FR**  
(city and either US State, if applicable, or country)

Mailing address : **8 rue du Maréchal Lefebvre, 34170 Castelnau-Le-Lez, France**

Citizenship : **FR**

Inventor's Signature : .....

Date : **24/04/2004** .....

Name :

Residence :  
(city and either US State, if applicable, or country)

Mailing address :

Citizenship :

Inventor's Signature : .....

Date : .....